Cargando…
Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature
INTRODUCTION: Intravascular large B-cell lymphoma is a rare aggressive disseminated disease characterized by the presence of lymphoma cells in small vessels without lymphadenopathy. Rituximab, a novel monoclonal antibody against the CD20 B-cell antigen, has been reported to be effective in treating...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923559/ https://www.ncbi.nlm.nih.gov/pubmed/24377366 http://dx.doi.org/10.1186/1752-1947-7-280 |
_version_ | 1782303625969664000 |
---|---|
author | Makino, Katsuhiro Nakata, Jumi Kawachi, Satoru Hayashi, Tatsuyuki Nakajima, Atsuo Yokoyama, Munehiro |
author_facet | Makino, Katsuhiro Nakata, Jumi Kawachi, Satoru Hayashi, Tatsuyuki Nakajima, Atsuo Yokoyama, Munehiro |
author_sort | Makino, Katsuhiro |
collection | PubMed |
description | INTRODUCTION: Intravascular large B-cell lymphoma is a rare aggressive disseminated disease characterized by the presence of lymphoma cells in small vessels without lymphadenopathy. Rituximab, a novel monoclonal antibody against the CD20 B-cell antigen, has been reported to be effective in treating intravascular large B-cell lymphoma. However, adverse events have been reported in association with rituximab infusion. CASE PRESENTATION: We report the case of a 54-year-old Japanese man diagnosed with Asian variant intravascular large B-cell lymphoma who died within five hours of the initiation of a first course of chemotherapy including rituximab. Autopsy results suggested that the patient died of severe systemic inflammatory response syndrome. A literature review revealed that rituximab administered during the second course of chemotherapy (instead of during the first course) appears to reduce the incidence of infusion reactions (from 48% to 15%) without altering the frequency of complete remission outcomes. CONCLUSIONS: Our data indicate that the incidence of adverse reactions to rituximab can be markedly decreased if the tumor load is first reduced with an initial course of chemotherapy excluding rituximab. Future prospective studies of the timing of rituximab administration are warranted. |
format | Online Article Text |
id | pubmed-3923559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39235592014-02-14 Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature Makino, Katsuhiro Nakata, Jumi Kawachi, Satoru Hayashi, Tatsuyuki Nakajima, Atsuo Yokoyama, Munehiro J Med Case Rep Case Report INTRODUCTION: Intravascular large B-cell lymphoma is a rare aggressive disseminated disease characterized by the presence of lymphoma cells in small vessels without lymphadenopathy. Rituximab, a novel monoclonal antibody against the CD20 B-cell antigen, has been reported to be effective in treating intravascular large B-cell lymphoma. However, adverse events have been reported in association with rituximab infusion. CASE PRESENTATION: We report the case of a 54-year-old Japanese man diagnosed with Asian variant intravascular large B-cell lymphoma who died within five hours of the initiation of a first course of chemotherapy including rituximab. Autopsy results suggested that the patient died of severe systemic inflammatory response syndrome. A literature review revealed that rituximab administered during the second course of chemotherapy (instead of during the first course) appears to reduce the incidence of infusion reactions (from 48% to 15%) without altering the frequency of complete remission outcomes. CONCLUSIONS: Our data indicate that the incidence of adverse reactions to rituximab can be markedly decreased if the tumor load is first reduced with an initial course of chemotherapy excluding rituximab. Future prospective studies of the timing of rituximab administration are warranted. BioMed Central 2013-12-30 /pmc/articles/PMC3923559/ /pubmed/24377366 http://dx.doi.org/10.1186/1752-1947-7-280 Text en Copyright © 2013 Makino et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Makino, Katsuhiro Nakata, Jumi Kawachi, Satoru Hayashi, Tatsuyuki Nakajima, Atsuo Yokoyama, Munehiro Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature |
title | Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature |
title_full | Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature |
title_fullStr | Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature |
title_full_unstemmed | Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature |
title_short | Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature |
title_sort | treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large b-cell lymphoma: a case report and review of the literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923559/ https://www.ncbi.nlm.nih.gov/pubmed/24377366 http://dx.doi.org/10.1186/1752-1947-7-280 |
work_keys_str_mv | AT makinokatsuhiro treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature AT nakatajumi treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature AT kawachisatoru treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature AT hayashitatsuyuki treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature AT nakajimaatsuo treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature AT yokoyamamunehiro treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature |